FCGR3A and carcinoma: They also demonstrated that ALT-803, at the highest dose (25 ng/mL), significantly enhanced NEO-201-mediated ADCC at both E:T ratios in all human carcinoma cell lines, compared to untreated cells (Fig. 2), and that ADCC mediated by NEO-201 enhanced by ALT-803 is dependent on CD16 engagement (Fig. 4).